CSF2 and leukemia: In ex vivo experiments using T-cell-enriched mixed-lymphocyte culture (MLC) from AML patients’ WB, Kit M (containing Granulocyte–Macrophage Colony-Stimulating-Factor (GM-CSF) and Prostaglandin E1(PGE1))-induced DCleu, which present the patients’ specific leukemic antigens, has been shown to induce leukemia-specific/antileukemic immune responses [17,18,19].